Scientific Evidence for EBT

When heart disease treatment is focused on patients who already have symptoms, doctors are delivering “sick care,” not health care.  To effectively treat heart disease, we need a way to identify patients who are asymptomatic but are already in the early stages of the disease.

In a study of more than 25,000 individuals with no symptoms of heart disease, almost one quarter had coronary calcium scores greater than 100.  Elevated coronary calcium correlated strongly with increased mortality – up to a 12-fold higher risk over seven years.

Over the past 20 years, research has demonstrated that EBT is the most accurate way to detect and measure coronary artery calcium.  As a result, EBT is the only technology approved by the federal Food and Drug Administration (FDA) for early detection of heart disease.  The American Heart Association, in a Scientific Statement, reaffirmed EBT as the reference standard for measurement of calcified coronary plaque.

In July 2006, the SHAPE Task Force – a group of the nation’s leading cardiologists – recommended that men between 45 and 75, and women between 55 and 75, be screened for subclinical atherosclerosis.  The Task Force predicts that such screening could save 90,000 lives a year and avoid more than $21.5 billion in treatment costs for heart disease. 

The SHAPE Guideline has been endorsed by many cardiologists in the Puget Sound region.

Coronary Artery Disease

The risk of death from heart disease increases in direct proportion to the amount of coronary calcium.